Does biochemical screening for non-adherence identify pseudo-resistant hypertension and alter eligibility in patients referred for renal denervation?
34 patients referred for renal denervation for apparent resistant hypertension
Biochemical screening for adherence to antihypertensive treatment using high-performance liquid chromatography-tandem mass spectrometry-based urine analysis
Standard clinical assessment without biochemical screening (hypothetical comparison)
Prevalence of non-adherence to antihypertensive treatment and eligibility rate for renal denervation
Biochemical screening for medication non-adherence reveals that over half of patients referred for renal denervation have pseudo-resistant hypertension, significantly reducing unnecessary procedures.
Renal denervation is a potential therapeutic option for resistant hypertension. A thorough clinical assessment to exclude reversible/spurious causes of resistance to antihypertensive therapy is required prior to this procedure. The extent to which non-adherence to antihypertensive treatment contributes to apparent resistance to antihypertensive therapy in patients considered for renal denervation is not known. Patients (n=34) referred for renal denervation entered the evaluation pathway that included screening for adherence to antihypertensive treatment by high-performance liquid chromatography-tandem mass spectrometry-based urine analysis. Biochemical non-adherence to antihypertensive treatment was the most common cause of non-eligibility for renal denervation-23.5% of patients were either partially or completely non-adherent to prescribed antihypertensive treatment. About 5.9% of those referred for renal denervation had admitted non-adherence prior to performing the screening test. Suboptimal pharmacological treatment of hypertension and 'white-coat effect' accounted for apparently resistant hypertension in a further 17.7 and 5.9% of patients, respectively. Taken together, these three causes of pseudo-resistant hypertension accounted for 52.9% of patients referred for renal denervation. Only 14.7% of referred patients were ultimately deemed eligible for renal denervation. Without biochemical screening for therapeutic non-adherence, the eligibility rate for renal denervation would have been 38.2%. Non-adherence to antihypertensive treatment and other forms of therapeutic pseudo-resistance are by far the most common reason of 'resistant hypertension' in patients referred for renal denervation. We suggest that inclusion of biochemical screening for non-adherence to antihypertensive treatment may be helpful in evaluation of patients with 'resistant hypertension' prior to consideration of renal denervation.
Building similarity graph...
Analyzing shared references across papers
Loading...
Prashanth Patel
Pankaj Gupta
Christobelle White
Journal of Human Hypertension
University College London
University of Leicester
National Institute for Health Research
Building similarity graph...
Analyzing shared references across papers
Loading...
Patel et al. (Thu,) studied this question.
www.synapsesocial.com/papers/69d56fbf75589c71d767daed — DOI: https://doi.org/10.1038/jhh.2015.103